Merck receives positive European Union CHMP opinion for Gefapixant
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
The CHMP’s recommendation will now be reviewed by the European Commission for marketing authorization in the European Union
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Subscribe To Our Newsletter & Stay Updated